This study investigates the observed discrepancy between real and perceived commercial risks associated with the use of genetically modified (GM) products in developing countries.
It focus particularly on the effects of GM-free private standards set up by food companies in Europe and other countries on biotechnology and biosafety policy decisions in food-exporting developing countries.
